These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 25580427)
1. Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation. Ma J; Yang J; Wang C; Zhang N; Dong Y; Wang C; Wang Y; Lin X Biomed Res Int; 2014; 2014():107671. PubMed ID: 25580427 [TBL] [Abstract][Full Text] [Related]
2. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374 [TBL] [Abstract][Full Text] [Related]
3. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Wang W; Sun YP; Huang XZ; He M; Chen YY; Shi GY; Li H; Yi J; Wang J Biochem Pharmacol; 2010 Apr; 79(8):1134-40. PubMed ID: 20005210 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation. Wang H; Li X; Chen T; Wang W; Liu Q; Li H; Yi J; Wang J Oncol Rep; 2013 Feb; 29(2):676-84. PubMed ID: 23229154 [TBL] [Abstract][Full Text] [Related]
5. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949 [TBL] [Abstract][Full Text] [Related]
6. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Yang YI; Kim JH; Lee KT; Choi JH Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308 [TBL] [Abstract][Full Text] [Related]
7. Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Li XX; Dong Y; Wang W; Wang HL; Chen YY; Shi GY; Yi J; Wang J Stem Cells Dev; 2013 Feb; 22(4):554-66. PubMed ID: 22974371 [TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Jiao JW; Wen F Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells. Lee C Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442 [TBL] [Abstract][Full Text] [Related]
10. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway. Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904 [TBL] [Abstract][Full Text] [Related]
12. Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression. Wang W; Sun Y; Li X; Li H; Chen Y; Tian Y; Yi J; Wang J Oncol Rep; 2011 Nov; 26(5):1143-8. PubMed ID: 21769433 [TBL] [Abstract][Full Text] [Related]
13. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer]. Qi C; Zhang QH; Li JX Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111 [TBL] [Abstract][Full Text] [Related]
14. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Tatebe S; Sinicrope FA; Kuo MT Biochem Biophys Res Commun; 2002 Feb; 290(5):1427-33. PubMed ID: 11820781 [TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751 [TBL] [Abstract][Full Text] [Related]
17. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Song K; Li Z; Seth P; Cowan KH; Sinha BK Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008 [TBL] [Abstract][Full Text] [Related]
18. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance]. Zhou Y; Chen H; Yang Q Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551 [TBL] [Abstract][Full Text] [Related]
19. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Ali AY; Abedini MR; Tsang BK Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021 [TBL] [Abstract][Full Text] [Related]
20. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]